SCHEMBL2479873

SCHEMBL2479873

CCN(CCc1ccccc1)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.59
MEN1 O00255 1/20 0.58
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
KMT2A Q03164 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
CHRM2 P08172 1/20 0.53
HTR1A P08908 1/20 0.53
ADRA2A P08913 1/20 0.53
CHRM1 P11229 1/20 0.53
DRD1 P21728 1/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53
ADRA1A P35348 1/20 0.53
OPRM1 P35372 1/20 0.53
DRD3 P35462 1/20 0.53
SLC6A3 Q01959 1/20 0.53
KCNH2 Q12809 1/20 0.53
AOC3 Q16853 1/20 0.53
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5933377 0.88 TDP1 (0.66) LMNAMEN1NPC1RAB9AKMT2A
SCHEMBL27821149 0.85 AOC3 (0.55) LMNAMEN1NPC1RAB9AKMT2A
SCHEMBL7228409 0.84 MEN1 (0.61) LMNAMEN1NPC1RAB9AKMT2A
SCHEMBL4333760 0.82 AOC3 (0.51) LMNAMEN1NPC1RAB9AKMT2A
SCHEMBL27288572 0.82 NPC1 (0.81) LMNAMEN1NPC1RAB9AKMT2A
SCHEMBL2693605 0.82 CYP1A2 (0.56) LMNAALDH1A1CA12CA1CA2
SCHEMBL1195514 0.82 LMNA (0.78) LMNAMEN1NPC1RAB9AKMT2A
SCHEMBL1570127 0.81 TAAR1 (0.57) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL28789696 0.81 KMT2A (0.50) LMNAMEN1NPC1RAB9AKMT2A
SCHEMBL7600830 0.81 MEN1 (0.54) LMNAMEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116338017-A Control method of levetiracetam impurity 浙江华海药业股份有限公司 2023-06-27 CN claimed
EP-2378601-B1 ELECTROLYTE CONTAINING A EUTECTIC MIXTURE AND A SPECIFIC NITRILE COMPOUND, AND ELECTROCHEMICAL DEVICE COMPRISING THE SAME LG CHEMICAL LTD (KR) 2016-03-30 EP claimed
US-8808924-B2 Electrolyte comprising eutectic mixture and secondary battery using the same LG CHEM, LTD. (KR) 2014-08-19 US claimed
US-20130172187-A1 USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS NORTH CAROLINA STATE UNIVERSITY 2013-07-04 US claimed
EP-2378601-A2 ELECTROLYTE CONTAINING EUTECTIC MIXTURE AND NITRILE COMPOUND AND ELECTROCHEMICAL DEVICE FURNISHED WITH THE SAME LG Chem, Ltd. (KR) 2011-10-19 EP claimed
US-20100304222-A1 ELECTROLYTE HAVING EUTECTIC MIXTURE AND NITRILE COMPOUND, AND ELECTROCHEMICAL DEVICE CONTAINING THE SAME LG ENERGY SOLUTION, LTD. (KR) 2010-12-02 US claimed
US-20100239917-A1 ELECTROLYTE COMPRISING EUTECTIC MIXTURE AND SECONDARY BATTERY USING THE SAME LG CHEM, LTD. (KR) 2010-09-23 US claimed
WO-2008088167-A1 ELECTROLYTE COMPRISING EUTECTIC MIXTURE AND SECONDARY BATTERY USING THE SAME LG CHEM, LTD. (KR) 2008-07-24 WO claimed
JP-6298605-A None JP disclosed
EP-3810772-B1 NOVEL URETHANASES FOR THE ENZYMATIC DECOMPOSITION OF POLYURETHANES COVESTRO DEUTSCHLAND AG (DE) 2025-10-29 EP disclosed
EP-4504931-A1 NOVEL URETHANASES FOR THE ENZYMATIC DEGRADATION OF POLYURETHANES Covestro Deutschland AG (DE) 2025-02-12 EP disclosed
EP-4355820-A1 METHOD FOR CLEAVING POLYURETHANE PRODUCTS Covestro Deutschland AG (DE) 2024-04-24 EP disclosed
WO-2023194440-A1 NOVEL URETHANASES FOR THE ENZYMATIC DEGRADATION OF POLYURETHANES COVESTRO DEUTSCHLAND AG (DE) 2023-10-12 WO disclosed
EP-4257683-A1 NOVEL URETHANASES FOR THE ENZYMATIC DECOMPOSITION OF POLYURETHANES Covestro Deutschland AG (DE) 2023-10-11 EP disclosed
US-20100239917-A1 ELECTROLYTE COMPRISING EUTECTIC MIXTURE AND SECONDARY BATTERY USING THE SAME LG CHEM, LTD. (KR) 2010-09-23 US disclosed
WO-2008088167-A1 ELECTROLYTE COMPRISING EUTECTIC MIXTURE AND SECONDARY BATTERY USING THE SAME LG CHEM, LTD. (KR) 2008-07-24 WO disclosed
US-5817641-A Treatment of enterotoxigenic diarrhea with 2-substituted adenosine derivatives THOMAS JEFFERSON UNIVERSITY (US) 1998-10-06 US disclosed
WO-1996003134-A1 TREATMENT OF DIARRHEA WITH 2-SUBSTITUTED ADENOSINE DERIVATIVES THOMAS JEFFERSON UNIVERSITY (US) 1996-02-08 WO disclosed
JP-H06298605-A BIO-FILM FORMATION-INHIBITING AGENT CONTAINING BETA-PHENETHYLAMINE DERIVATIVE AS ACTIVE INGREDIENT SAGAMI CHEM RES CENTER 1994-10-25 JP disclosed
US-4654347-A USEFUL AS ANXIOLYTIC AND ANTIEPILEPTIC AGENTS, SEDATIVE-HYPNOTIC AGENTS AND SKELETAL MUSCLE RELAXANTS AMERICAN CYANAMID COMPANY (US) 1987-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172187-A1 USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS CTRC, ACE, DDT LMNA 4641/4885MEN1 4199/4885NPC1 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.